Recombinant Factor VIII Half-Life Extension via Permissive Loop Modification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemophilia A and B, which involve frequent intravenous administration of recombinant Factor VIII and IX proteins, are painful and inconvenient due to the short half-life of these proteins, leading to progressive joint damage and debilitating immobility in patients.
Innovation Solution
A recombinant FVIII protein is developed with specific amino acid substitutions or deletions in permissive loops and the A1-1 region, combined with a heterologous moiety insertion, which extends the protein's half-life and stability, allowing for less frequent administration while maintaining procoagulant activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If frequent intravenous administration is used to maintain FVIII activity levels, then bleeding prevention is achieved, but patient convenience and quality of life deteriorate due to pain and inconvenience
Solution Approach 1:
The patent modifies the FVIII protein structure by inserting heterologous moieties (such as PEG chains or albumin-binding domains) and making amino acid substitutions in permissive loops, thereby changing the pharmacokinetic parameters of the protein to extend its half-life from approximately 8-12 hours to 3-5 days or longer, allowing less frequent administration
Solution Approach 2:
The invention creates composite protein structures by fusing FVIII with heterologous moieties (e.g., polyethylene glycol chains, albumin-binding peptides), forming chimeric molecules that combine the procoagulant function of FVIII with the extended circulation properties of the heterologous components
2Duration of action of stationary object
If amino acid substitutions and heterologous moiety insertion are made in FVIII, then half-life and stability are extended, but protein structure complexity increases
Solution Approach 1:
The patent applies modifications only to specific permissive loops and regions of the FVIII protein (such as loops in the A1, A2, A3, or C1 domains) that are tolerable to structural change, leaving the critical functional domains intact, thereby extending half-life without compromising overall protein function or excessive complexity
3Reliability
If frequent administration is required due to short half-life, then FVIII activity can be maintained, but progressive joint damage and immobility worsen due to treatment burden
Solution Approach 1:
By extending the half-life of FVIII through structural modifications (PEGylation, albumin-binding fusion), the patent enables maintenance of therapeutic FVIII levels for 3-5 days or longer with each administration, reducing the frequency of injections and allowing better joint protection through sustained hemostatic coverage
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
Provided are recombinant Factor VIII proteins, e.g., human Factor VIII proteins, in which one or more amino acids in at least one permissive loops or a3 domain are substituted or deleted, or replaced with heterologous moieties, while retaining the procoagulant activity of Factor VIII.